Monday, 16 Sep 2019

You are here

Respiratory Risks Not Increased in RA Patients with COPD

An insurance claims based study of rheumatoid arthritis (RA) patients with chronic obstructive pulmonary disease (COPD) shows that biologics do not have an increased rate of respiratory events compared to those on conventional DMARDs.

A real world cohort of RA patients with COPD was drawn from US-based MarketScan databases. Patients on biologic DMARDs and/or targeted synthetic DMARDs (tsDMARDs) were propensity matched to those on conventional synthetic DMARDs (csDMARDs).

The study compared 7424 RA/COPD patients initiating biologic/tsDMARDs to 7424 patients initiating csDMARDs.

Comparing biologic/tsDMARD vs csDMARD shows the adjusted hazard ratio for:

  • hospitalized COPD exacerbation = 0.76 (95% CI: 0.55, 1.06)
  • bronchitis = HR 1.02 (95% CI: 0.82, 1.27)
  • hospitalized pneumonia or influenza = 1.21 (95% CI: 0.92, 1.58)
  • outpatient pneumonia or influenza=  0.99 (95% CI: 0.87, 1.12)

The hazard ratio of the combined end point of COPD exacerbation, bronchitis and hospitalized pneumonia or influenza was 1.04 (95% CI: 0.89, 1.21).

Biologic and tsDMARDs appear to be safe to use in RA patients with COPD, having a low risk of adverse respiratory events.

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Two vs. Four Weeks of Antibiotic Therapy in Septic Arthritis

A prospective trial has shown that 2 weeks of antibiotic therapy is as effective as 4 weeks of antibiotic therapy, with similar outcomes but shorter hospital stays.

This Swiss study was a prospective, unblinded, randomised, non-inferiority study comparing either 2 or 4 weeks of antibiotic therapy after surgical drainage of native joint bacterial arthritis in adults. 

Bimekizumab Add-on Therapy in Rheumatoid Arthritis

Bimekizumab is a dual inhibitor of IL-17A and IL-17F that has been shown to be effective in psoriasis and psoriatic arthritis. A proof-of-concept study shows that giving bimekizumab to rheumatoid arthritis patients not adequately controlled by certolizumab pegol resulted in a rapid decrease in disease activity achieved after 12 weeks of treatment. These findings are novel as anti-IL-17 monoclonal antibody therapy has previously been shown to be ineffective in RA.

74 Percent of Rheumatoid Arthritis Patients Dissatisfied with Treatment

CreakyJoints has completed a 258 patient survey showing that nearly three-fourths of people with rheumatoid arthritis (RA) have expressed dissatisfaction with their treatments, including conventional (csDMARDs) and biologic Disease Modifying Antirheumatic Drugs (bDMARDs).

RA Women are Less Likely to Breastfeed

A large pregnancy registry has published their results showing rheumatoid arthritis (RA) patients who become pregnant are less likely to breastfeed compared to non-RA women from the general population, with many women stopping breastfeeding so that they could start medication, even though many of these meds are safe to use during lactation.

Tocilizumab Shows No Increase in Cardiovascular Risk

The ENTRACTE trial examined the risk for major adverse cardiovascular events (MACE) in RA patients and found no increased risk of MACE in patients treated with tocilizumab (TCZ) versus etanercept (ETN).

The trial was undertaken to examine the CV consequences of the hyperlipidemia seen in up to 20% of patientstreated with IL-6 inhibitors.